Matinas BioPharma Holdings (MTNB) Current Deferred Revenue (2015 - 2022)
Matinas BioPharma Holdings (MTNB) reported Current Deferred Revenue of $721000.0 for Q4 2022, up 2308.39% quarter-over-quarter from $29937.0 in Q4 2017.
Matinas BioPharma Holdings (MTNB) Current Deferred Revenue (2015 - 2022) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has 4 years of Current Deferred Revenue data on file, last reported at $721000.0 in Q4 2022.
- Current Deferred Revenue for Q4 2022 came in at $721000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2022 was $721000.0 (changed N/A YoY), and the FY2022 annual result was $721000.0, changed N/A from the prior year.
- Current Deferred Revenue improved to $721000.0 in Q4 2022 per MTNB's latest filing, from $29937.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $721000.0 in Q4 2022 and troughed at $721000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Matinas BioPharma Holdings | 4.60 Mn | 2.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 721,000.00 |
| Dec 31, 2017 | 29,937.00 |
| Sep 30, 2017 | 74,844.00 |
| Jun 30, 2017 | 119,750.00 |
| Mar 31, 2017 | 164,656.00 |
| Dec 31, 2016 | 11,485.00 |
| Sep 30, 2016 | 11,226.00 |
| Jun 30, 2016 | 10,967.00 |
| Mar 31, 2016 | 10,218.00 |
| Dec 31, 2015 | 9,225.00 |
| Sep 30, 2015 | 8,232.00 |
| Jun 30, 2015 | 7,239.00 |
| Mar 31, 2015 | 5,757.00 |